PMID- 22506682
OWN - NLM
STAT- MEDLINE
DCOM- 20121227
LR  - 20131103
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 9
IP  - 4
DP  - 2012 Aug
TI  - The prevalence of alpha-1 antitrypsin deficiency among patients found to have 
      airflow obstruction.
PG  - 352-8
LID - 10.3109/15412555.2012.669433 [doi]
AB  - INTRODUCTION: Alpha-1 antitrypsin deficiency (AATD) is a genetic disease that may 
      be manifested by chronic obstructive pulmonary disease. Despite professional 
      society guidelines that recommend broad testing of at-risk individuals, fewer 
      than 10% of affected individuals have been identified. The goals of this study 
      were to estimate the frequency of abnormal AAT genotypes among patients found to 
      have fixed airflow obstruction and to assess the feasibility of having Pulmonary 
      Function Laboratory personnel administer the study. METHODS: Nineteen medical 
      centers in the United States participated in the study. Eligible patients (> GOLD 
      II, FEV(1)/FVC ratio < 0.7, with post-bronchodilator FEV(1)<80% predicted) were 
      offered testing for AATD by the Pulmonary Function Laboratory personnel at the 
      time of pulmonary function testing. RESULTS: A total of 3,457 patients were 
      tested, of whom 3152 were eligible. Deficient patients (ZZ, SZ) constituted 0.63% 
      of subjects, while 10.88% were carriers (MS, MZ). Neither demographic (except 
      African-American race) nor post-bronchodilator pulmonary function variables 
      (FEV(1), FVC, FEV(1)/FVC ratio, TLC, and FEV(1)/FVC) allowed us to predict AAT 
      heterozygote or deficiency status. CONCLUSIONS: The prevalence of AATD among 
      patients undergoing pulmonary function tests with fixed airflow obstruction was 
      0.63%. Pulmonary Function Laboratory personnel effectively conducted the study.
FAU - Rahaghi, Franck F
AU  - Rahaghi FF
AD  - Cleveland Clinic Florida, Pulmonary and Critical Care, Weston, Florida 33332, 
      USA. rahaghf@ccf.org
FAU - Sandhaus, Robert A
AU  - Sandhaus RA
FAU - Brantly, Mark L
AU  - Brantly ML
FAU - Rouhani, Farshid
AU  - Rouhani F
FAU - Campos, Michael A
AU  - Campos MA
FAU - Strange, Charlie
AU  - Strange C
FAU - Hogarth, Douglas Kyle
AU  - Hogarth DK
FAU - Eden, Edward
AU  - Eden E
FAU - Stocks, James M
AU  - Stocks JM
FAU - Krowka, Michael J
AU  - Krowka MJ
FAU - Stoller, James K
AU  - Stoller JK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120416
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Genetic Markers)
RN  - 0 (alpha 1-Antitrypsin)
SB  - IM
EIN - COPD. 2013 Aug;10(4):555. Brantly, Mark L [added]; Rouhani, Farshid [added]; 
      Campos, Michael A [added]
MH  - Aged
MH  - Feasibility Studies
MH  - Female
MH  - Genetic Markers
MH  - Genotype
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Medical Laboratory Personnel
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/*etiology
MH  - Respiratory Function Tests
MH  - Respiratory Therapy Department, Hospital
MH  - alpha 1-Antitrypsin/*genetics
MH  - alpha 1-Antitrypsin Deficiency/complications/*diagnosis/epidemiology/genetics
EDAT- 2012/04/18 06:00
MHDA- 2012/12/28 06:00
CRDT- 2012/04/18 06:00
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2012/12/28 06:00 [medline]
AID - 10.3109/15412555.2012.669433 [doi]
PST - ppublish
SO  - COPD. 2012 Aug;9(4):352-8. doi: 10.3109/15412555.2012.669433. Epub 2012 Apr 16.